Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 1Phase 2/3 1

Status

Completed 31Terminated 13Unknown 6Active not recruiting 5Withdrawn 4Recruiting 4Not yet recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 4Endocrine 1Breast 1

Conditions

Prostatic Neoplasms 3Prostatic Neoplasms, Castration-Resistant 1Neoplastic Cells, Circulating 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Cisplatin 267Oxaliplatin 194Carboplatin 189Capecitabine 183Docetaxel 176apatinib 164Paclitaxel 158Bevacizumab 155Gemcitabine 154Radiotherapy 146camrelizumab 145Fluorouracil 144Cyclophosphamide 123Irinotecan 119Drug Therapy 118sintilimab 107Etoposide 99anlotinib 90S 1 (combination) 88Leucovorin 85pembrolizumab 82Pemetrexed 78Doxorubicin 77toripalimab 76tislelizumab 75Dexamethasone 70Trastuzumab 65Neoadjuvant Therapy 64Rituximab 62Cetuximab 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Unknown × cabazitaxel × Clear all
NCT03050866 2021-08-20

CABA-V7

Erasmus Medical Center

Phase 2 Unknown
140 enrolled
Genitourinary

Neoplastic Cells, Circulating, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT04622761 2021-01-05

CHROME

The Clatterbridge Cancer Centre NHS Foundation Trust

Phase 2 Unknown
120 enrolled
Genitourinary

Prostatic Neoplasms

NCT03048942 2019-11-13

CONCEPT

University Hospitals Bristol and Weston NHS Foundation Trust

Phase 2 Unknown
160 enrolled
Breast

Breast Neoplasms

NCT03257891 2018-04-11

CabACC

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Phase 2 Unknown
25 enrolled
Endocrine

Adrenocortical Carcinoma

NCT03356912 2017-12-14

CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy

Consorzio Oncotech

Phase 2 Unknown
220 enrolled
Genitourinary

Prostatic Neoplasms

NCT02254785 2017-12-06

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

British Columbia Cancer Agency

Phase 2 Unknown
120 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡